Coronary Artery Disease News and Research

Latest Coronary Artery Disease News and Research

New issue from Annals of Internal Medicine

Prescriptions of some opioids, such as oxycodone, have increased significantly over the past decade. As long-term opioid therapy for chronic noncancer pain becomes more common, the deaths associated with opioids increase.

19 Jan 2010

HDL launches new preventative model to help physicians manage chronic diseases

Health Diagnostic Laboratory Inc. (HDL), www.hdlabinc.com, announced today the launch of its new preventative model to chronic disease management based off a monumental shift in the way physicians test for life threatening conditions.

19 Jan 2010

U-M's tailored treatment more effective against heart attacks

A new study by the University of Michigan Medical School and VA Ann Arbor Health System challenges the medical thinking that the lower the cholesterol, the better.

19 Jan 2010

FDA approves Celsius RMT ThermoCool catheter for use with Stereotaxis' magnetic navigation system

Stereotaxis announced that the Celsius® RMT ThermoCool® catheter has been approved by the U.S. Food and Drug Administration for use with Stereotaxis' magnetic navigation system for the treatment of Type 1 atrial flutter. The product is the fifth advanced ablation catheter resulting from the on-going co-development agreement between Stereotaxis and Biosense Webster to design and distribute magnetically enabled catheters for mapping and ablation.

12 Jan 2010

Amarin commences enrollment in its AMR101 Phase 3 clinical trials for cardiovascular disease

Amarin Corporation plc, a clinical-stage biopharmaceutical company focused on improving the treatment of cardiovascular disease, today announced that first patients were enrolled in the MARINE and ANCHOR Phase 3 clinical trials for AMR101, the Company's lead product candidate. These clinical trials are designed to demonstrate that AMR101 lowers triglyceride levels in patients with very high triglycerides (the MARINE Study) and high triglycerides in patients with mixed dyslipidemia being treated with statins (the ANCHOR Study).

11 Jan 2010

European Society of Cardiology warns public about risk factors involved in obesity, diabetes and hypertension

Following the sudden death yesterday of the former French government minister Philippe Séguin, who suffered a fatal heart attack, aged 66, the European Society of Cardiology is warning the public of the dangers of leaving risk factors such as hyperlipidemia, hypertension or diabetes untreated. Other major risk factors for coronary artery disease are smoking or being overweight.

9 Jan 2010

Boston Scientific's PROMUS Everolimus-Eluting Coronary Stent System receives Japanese marketing approval

Boston Scientific Corporation announced today that it has received approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) to market its PROMUS® Everolimus-Eluting Coronary Stent System for the treatment of coronary artery disease. The Company plans to launch the product as soon as reimbursement approval is granted, which is expected in the coming weeks.

9 Jan 2010

VA expected to move soon to cover more effects of Agent Orange

The Department of Veterans Affairs may need to pay heavily to treat veterans who have been adversely affected by Agent Orange. McClatchy/Beaufort (S.C.) Gazette report: "The cost of war -- on veterans' health and taxpayer wallets -- will loom a little larger in the new year when the Department of Veterans Affairs issues a final rule to claim adjudicators to presume three more diseases of Vietnam veterans, including heart disease, were caused by exposure to Agent Orange.

8 Jan 2010

Japanese MHLW approves Abbott's XIENCE V Everolimus Eluting Coronary Stent System

Abbott announced today that the Japanese Ministry of Health, Labor and Welfare (MHLW) has approved its XIENCE V® Everolimus Eluting Coronary Stent System for the treatment of coronary artery disease.

8 Jan 2010

Young men with HIV infection have coronary atherosclerotic plaques: MGH study

A Massachusetts General Hospital (MGH) study has found that relatively young men with longstanding HIV infection and minimal cardiac risk factors had significantly more coronary atherosclerotic plaques - some involving serious arterial blockage - than did uninfected men with similar cardiovascular risk.

8 Jan 2010

Researchers identify new approach to eliminate side effects of drugs

Researchers at the Stanford University School of Medicine have taken an early step toward identifying a new approach to drug discovery that may eventually yield drugs with fewer side effects.

7 Jan 2010

NewCardio announces two encouraging validation studies related to CardioBip

NewCardio, Inc., a cardiac diagnostic technology provider, announced today two encouraging validation studies related to CardioBip(TM), a hand-held patient-activated device for recording and wireless transmission of reconstructed 12-lead ECGs.

6 Jan 2010

Boston Scientific commences enrollment in its TAXUS Liberte Stent System study

Boston Scientific Corporation today announced that it has enrolled the first patient in its TAXUS Liberte post-approval study. The study is designed to evaluate real-world clinical outcomes data for the TAXUS® Liberte® Paclitaxel-Eluting Coronary Stent System in combination with a dual antiplatelet therapy drug regimen that includes aspirin and Effient®, a new antiplatelet medication. Co-sponsors of the study include Eli Lilly and Company and Daiichi Sankyo, Inc., manufacturers of Effient, which was recently approved by the U.S. Food and Drug Administration (FDA).

4 Jan 2010

Cardiogenesis submits an IDE for its PHOENIX System

Cardiogenesis Corporation, today announced that it has submitted an IDE (Investigational Device Exemption) to the Food and Drug Administration to initiate a safety and feasibility trial for its PHOENIX System in patients with refractory angina. The PHOENIX handpiece is the first device specifically designed to allow physician-directed tissue stimulation and injections of biologic or pharmacologic agents to pre-determined areas of myocardium.

4 Jan 2010

JAMA: New series on caring for the aging patient

To assist physicians in caring for a patient demographic that is rapidly growing in size, JAMA is launching a new series, "Care of the Aging Patient: From Evidence to Action."

29 Dec 2009

Eli Lilly and Kowa Pharmaceuticals America to co-promote LIVALO in the U.S

Eli Lilly and Company (NYSE: LLY), Kowa Company, Limited, and Kowa's U.S. subsidiary, Kowa Pharmaceuticals America, Inc., today announced that Lilly and Kowa Pharmaceuticals America have entered into a co-promotion agreement in the United States to commercialize LIVALO® (pitavastatin). Lilly and Kowa have also entered into a licensing agreement in Latin America. LIVALO is a statin approved by the U.S. Food and Drug Administration (FDA) in August 2009 for the treatment of primary hyperlipidemia and mixed dyslipidemia.

24 Dec 2009

Volcano lauds revised guidelines for treating severe coronary artery disease patients

Volcano Corporation, a leader in the development, manufacturing and sales of products for the diagnosis and treatment of coronary and peripheral artery disease, reacted positively to the new guidelines for treating coronary disease and heart attacks using percutaneous coronary intervention (PCI), a procedure that treats narrowed blood vessels.

23 Dec 2009

Study reveals patient characteristics can affect image quality of MDCT scans

A large multicenter international trial found that the image quality of multi-detector computed tomography (MDCT) scans, used for the noninvasive detection of coronary artery disease, can be significantly affected by patient characteristics such as ethnicity, body mass index (BMI), and heart rate, according to a study in the January issue of the American Journal of Roentgenology.

23 Dec 2009

US Phase 2 clinical trial of RVX-208 commenced by Resverlogix

Resverlogix Corp. ("Resverlogix" or the "Company") announced today that it has begun dosing patients in its US Phase 2 clinical trial lead by Cleveland Clinic. This trial will examine RVX-208, Resverlogix's oral small molecule therapy for the treatment of atherosclerosis, in patients with stable coronary artery disease (CAD).

23 Dec 2009

MRG: Chinese drug-eluting stent market to reach more than $900 million by 2014

According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, health care reforms in China supported rapid expansion of the Chinese drug-eluting stent market in 2009, and will continue to fuel growth in the coming years.

17 Dec 2009

Coronary Artery Disease News and Research

Latest Coronary Artery Disease News and Research

New issue from Annals of Internal Medicine

HDL launches new preventative model to help physicians manage chronic diseases

U-M's tailored treatment more effective against heart attacks

FDA approves Celsius RMT ThermoCool catheter for use with Stereotaxis' magnetic navigation system

Amarin commences enrollment in its AMR101 Phase 3 clinical trials for cardiovascular disease

European Society of Cardiology warns public about risk factors involved in obesity, diabetes and hypertension

Boston Scientific's PROMUS Everolimus-Eluting Coronary Stent System receives Japanese marketing approval

VA expected to move soon to cover more effects of Agent Orange

Japanese MHLW approves Abbott's XIENCE V Everolimus Eluting Coronary Stent System

Young men with HIV infection have coronary atherosclerotic plaques: MGH study

Researchers identify new approach to eliminate side effects of drugs

NewCardio announces two encouraging validation studies related to CardioBip

Boston Scientific commences enrollment in its TAXUS Liberte Stent System study

Cardiogenesis submits an IDE for its PHOENIX System

JAMA: New series on caring for the aging patient

Eli Lilly and Kowa Pharmaceuticals America to co-promote LIVALO in the U.S

Volcano lauds revised guidelines for treating severe coronary artery disease patients

Study reveals patient characteristics can affect image quality of MDCT scans

US Phase 2 clinical trial of RVX-208 commenced by Resverlogix

MRG: Chinese drug-eluting stent market to reach more than $900 million by 2014

Leveraging the Radian ASAP in standard casework

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Coronary Artery Disease News and Research

Latest Coronary Artery Disease News and Research

Leveraging the Radian ASAP in standard casework

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Newsletters you may be interested in